Midterm Surging AIM ImmunoTech (NYSE: AIM) Still Developing Ampligen For COVID-19 Treatment

March 9, 2020, was a day with the drastic price change in NYSE: AIM but on next day it fell sharply. That phenomenal jump in stock price was caused by only one news related to combat the COVID-19 before the massive lockdown in the whole world. Since then AIM can’t be able to reach $3 line while Moderna’s stock soared to $62 until last Friday.

On Friday at the market opening AIM rose to $2.70 but at the close, no change happened so that Thursday’s $2.59 would remain. Today in pre-market: 6:09 AM EDT the stock fell by $0.01. Anytime the stock may rise due to most investors’ interests in the biotech industry.

Alex Krakowsky

Editor in Chief.Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life